Tempus AI
Tempus / tempus.com
AI-powered precision medicine platform analysing molecular and clinical data to personalise cancer treatment decisions, accelerate drug discovery, and match patients to clinical trials.
Pricing
Free
Free plan
No
Category
Developer Tools
Platforms
2
Free plan
No
API access
No
Open source
No
Platforms
2
Advertisement
What is Tempus AI?
Tempus is a data-driven oncology and precision medicine company with one of the largest libraries of clinical and molecular data, applying AI to help oncologists make more informed treatment decisions and help pharmaceutical companies identify patients for clinical trials. For oncologists, the AI platform analyses a patient's genomic sequencing results against a large database of similar patients to provide insights into which treatments have been associated with better outcomes in comparable cases. For pharmaceutical companies, Tempus's data platform identifies patients whose genomic and clinical profiles match clinical trial eligibility criteria, reducing patient recruitment time and cost. Tempus went public on NASDAQ (TEM) in 2024, reflecting its position as a significant player in AI-enabled precision medicine.
How Tempus AI works
Tempus AI runs as ml platform software built around data and text workflows. Users typically start with a prompt, upload, or connected data source, and the underlying model handles the heavy lifting before returning a result you can refine or export. It's available on web and api.
Watch Tempus AI in action
Recent YouTube videos cached from the backend so this page stays fast and fresh.
What makes it worth shortlisting
The capabilities that matter most for teams evaluating Tempus AI.
AI genomic analysis
Analyses RNA and DNA sequencing results against a large clinical database to surface treatment-relevant genomic insights for oncologists.
Clinical trial matching
Identifies patients whose genomic and clinical profiles match clinical trial eligibility criteria, reducing pharmaceutical patient recruitment time.
Real-world evidence database
Integrates clinical outcomes across patients in Tempus's database to provide comparative insights on treatment approaches.
Best use cases
Who should use it
Pros
- One of the largest clinical and molecular data libraries in oncology
- AI treatment insights grounded in real-world evidence from similar patients
- Clinical trial matching significantly reduces pharmaceutical patient recruitment costs
- Public company (NASDAQ: TEM) with strong financial validation
Cons
- Enterprise-only with high pricing inaccessible to small practices
- Primarily focused on oncology — less applicable in other disease areas
- AI insights are supportive tools, not clinical decision replacements requiring physician judgment
Advertisement
Is it worth the price?
Enterprise licensing to health systems, pharmaceutical companies, and research institutions. No public pricing.
Model
Enterprise
Starting price
Free
Free trial
No
Tools like Tempus AI
Foundation Medicine (Roche subsidiary) provides comparable genomic profiling. Flatiron Health (also Roche) provides oncology real-world data. IBM Watson for Oncology was a notable predecessor that faced clinical validation challenges.
Tempus AI vs Flatiron Health AI
A side-by-side look at the closest alternative in this category.
Tempus AI
Tempus
Flatiron Health AI
Flatiron Health (Roche)
Enterprise licensing to health systems, pharmaceutical companies, and research institutions. No public pricing.
Enterprise licensing to pharmaceutical companies and cancer centres. No public pricing. Subsidiary of Roche.
HIPAA compliant. SOC 2 Type II. ISO 27001. Patient genomic and clinical data handled under HIPAA protections with appropriate de-identification for research use.
HIPAA compliant with BAA. SOC 2 Type II. GDPR compliant for EU deployments. IRB approval for research datasets. FDA-accepted data quality standards.
Patient genomic and clinical data processed under HIPAA protections. Research use data is de-identified per HIPAA standards. Enterprise includes comprehensive data handling agreements.
Patient health data processed under strict HIPAA BAA and applicable research ethics frameworks. De-identification and IRB protocols govern research dataset access.
- One of the largest clinical and molecular data libraries in oncology
- AI treatment insights grounded in real-world evidence from similar patients
- Clinical trial matching significantly reduces pharmaceutical patient recruitment costs
- Public company (NASDAQ: TEM) with strong financial validation
- 9 million+ patient oncology database is one of the most comprehensive real-world oncology datasets available for pharmaceutical research
- FDA-accepted real-world evidence from multiple regulatory submissions provides unmatched regulatory validation
- NLP curation of clinical notes extracts structured data inaccessible through structured EHR data alone
- Roche ownership provides stability and pharmaceutical partnership pipeline
- Enterprise-only with high pricing inaccessible to small practices
- Primarily focused on oncology — less applicable in other disease areas
- AI insights are supportive tools, not clinical decision replacements requiring physician judgment
- Roche ownership creates potential conflict of interest concerns for pharmaceutical competitors as data partners
- Real-world evidence database access requires partnership agreements limiting accessibility
- Clinical note NLP accuracy requires ongoing validation — structured EHR data remains more reliable for some variables
Technical & deployment info
Key facts about model providers, platforms, and team support.
Model Provider
Tempus
Platforms
Web, API
Deployment
Enterprise
Integrations
EHR integrations, Pharmaceutical platforms, Research systems, API
Team Collaboration
Yes
Launch Year
2015
Security & privacy
Compliance signals and data-handling notes as reported by the vendor.
HIPAA compliant. SOC 2 Type II. ISO 27001. Patient genomic and clinical data handled under HIPAA protections with appropriate de-identification for research use.
Patient genomic and clinical data processed under HIPAA protections. Research use data is de-identified per HIPAA standards. Enterprise includes comprehensive data handling agreements.
What users are saying
Verified reviews from signed-in users, stored in the backend and averaged into this tool's rating.
Sign in to rate Tempus AI and leave a review.
No other reviews yet — be the first to share how this tool performs in practice.
Common questions about Tempus AI
Editorial Verdict
Should you use Tempus AI?
Tempus is the leading AI precision medicine platform for oncology, most relevant to major cancer centres, health systems with oncology programmes, and pharmaceutical companies for drug discovery and trial matching.
Last verified July 24, 2026.